Related references
Note: Only part of the references are listed.Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains A Systematic Review and Meta-analysis
Yu Wu et al.
JAMA NETWORK OPEN (2022)
Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver
Han-Yu Lei et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells
Shuai Wang et al.
CELL RESEARCH (2021)
Cyclin dependent kinase inhibitors as a new potential therapeutic option in management of COVID-19
Mohamed Gargouri et al.
MEDICAL HYPOTHESES (2021)
Prevalence of Covid-19 Associated Symptoms, Their Onset and Duration, and Variations Among Different Groups of Patients in Bangladesh
Md Tanzilul Amin et al.
FRONTIERS IN PUBLIC HEALTH (2021)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia
Qun Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Xiuyuan Ou et al.
NATURE COMMUNICATIONS (2020)
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study
Juanjuan Zhang et al.
LANCET INFECTIOUS DISEASES (2020)
Immunomodulation in COVID-19
Nicholas E. Ingraham et al.
LANCET RESPIRATORY MEDICINE (2020)
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Charles Pottier et al.
CANCERS (2020)
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease
Victor J. Costela-Ruiz et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2020)
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Yujun Tang et al.
FRONTIERS IN IMMUNOLOGY (2020)
COVID-19: Melatonin as a potential adjuvant treatment
Rui Zhang et al.
LIFE SCIENCES (2020)
Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients
Yong Xiong et al.
EMERGING MICROBES & INFECTIONS (2020)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv192, 2018)
D. Planchard et al.
ANNALS OF ONCOLOGY (2019)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018)
A. Vogel et al.
ANNALS OF ONCOLOGY (2019)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2019)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology
Stefania Crisci et al.
MEDICINA-LITHUANIA (2019)
Prediction and characterisation of lantibiotic structures with molecular modelling and molecular dynamics simulations
Hirak Jyoti Chakraborty et al.
SCIENTIFIC REPORTS (2019)
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study
Maximilian J. Hochmair et al.
FUTURE ONCOLOGY (2019)
The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy
Fan Liang et al.
ONCOGENESIS (2019)
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
Bhagirathbhai R. Dholaria et al.
BIODRUGS (2019)
p38α Mitogen-Activated Protein Kinase Is a Druggable Target in Pancreatic Adenocarcinoma
Ling Yang et al.
FRONTIERS IN ONCOLOGY (2019)
Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors
Zahra Moradpour et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2019)
Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
Ningning Zhang et al.
JOURNAL OF CANCER (2019)
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2018)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
Silvia Maifrede et al.
BLOOD (2018)
MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile
Waleed H. Mahallawi et al.
CYTOKINE (2018)
Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes
Zheng Yang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2018)
Targeting tumour microenvironment by tyrosine kinase inhibitor
Hor-Yue Tan et al.
MOLECULAR CANCER (2018)
Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar et al.
MOLECULAR CANCER (2018)
Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors
Anthony W. Tolcher et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells
Rui Wang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
FDA approves Eli Lilly's baricitinib
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2018)
Antiviral activity of ginsenoside Rg3 isomers against gammaherpesvirus through inhibition of p38-and JNK-associated pathways
Soowon Kang et al.
JOURNAL OF FUNCTIONAL FOODS (2018)
Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors
Pedro Miguel Lacal et al.
PHARMACOLOGICAL RESEARCH (2018)
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Toshimitsu Yamaoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Yi Ding et al.
NATURE COMMUNICATIONS (2018)
Pericytes Elicit Resistance to Vemur1afenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGF beta 1 Axis
Alessandro Prete et al.
CLINICAL CANCER RESEARCH (2018)
Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
Xian Yang Chan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Protein kinase C in cancer: The top five unanswered questions
Mariana Cooke et al.
MOLECULAR CARCINOGENESIS (2017)
Modulation of mitogen-activated protein kinase attenuates sepsis-induced acute lung injury in acute respiratory distress syndrome rats
Wei Fang et al.
MOLECULAR MEDICINE REPORTS (2017)
Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells
A. Miyazaki et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination
Jason S. L. Yu et al.
DEVELOPMENT (2016)
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
Steven S. Yu et al.
ONCOTARGETS AND THERAPY (2016)
The Receptor Tyrosine Kinase AXL in Cancer Progression
Erinn B. Rankin et al.
CANCERS (2016)
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Floriana Morgillo et al.
ESMO OPEN (2016)
Ten things you should know about protein kinases: IUPHAR Review 14
Doriano Fabbro et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
The importance of the tumor microenvironment in the therapeutic management of cancer
Charles Pottier et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity
Andrew L. Croxford et al.
IMMUNITY (2015)
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
L. Kalmanti et al.
LEUKEMIA (2015)
Understanding multicellular function and disease with human tissue-specific networks
Casey S. Greene et al.
NATURE GENETICS (2015)
Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
Peter B. Alexander et al.
FRONTIERS OF MEDICINE (2015)
Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
Julie Dyall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance
Edita Aksamitiene et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Severe Acute Respiratory Syndrome (SARS) Coronavirus-Induced Lung Epithelial Cytokines Exacerbate SARS Pathogenesis by Modulating Intrinsic Functions of Monocyte-Derived Macrophages and Dendritic Cells
Tomoki Yoshikawa et al.
JOURNAL OF VIROLOGY (2009)
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Nathan A. Pennell et al.
ONCOLOGIST (2009)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Resistance to c-KIT kinase inhibitors conferred by V654A mutation
Kathryn G. Roberts et al.
MOLECULAR CANCER THERAPEUTICS (2007)
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib
H. Kimura et al.
BRITISH JOURNAL OF CANCER (2006)
Src family kinases regulate p38 MAPK-mediated IL-6 production in Kupffer cells following hypoxia
Bjorn M. Thobe et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2006)
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance
J Chandra et al.
BLOOD (2006)
Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: Role of ciliated cells in viral spread in the conducting airways of the lungs
AC Sims et al.
JOURNAL OF VIROLOGY (2005)
High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors
E Mishani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A comprehensive pathway map of epidermal growth factor receptor signaling
Kanae Oda et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
State-of-the art therapy for gastrointestinal stromal tumors
CD Blanke et al.
CANCER INVESTIGATION (2005)
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
CK Wong et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2004)
Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer
M Shaul et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
WH Li et al.
NATURE (2003)
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours
D Checkley et al.
BRITISH JOURNAL OF CANCER (2003)
Epidermal growth factor receptor tyrosine kinase inhibitors
AE Wakeling
CURRENT OPINION IN PHARMACOLOGY (2002)
Novel 4-anilinoquinazolines with C-7 basic side chains:: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors
LF Hennequin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
CD8+ T cell-mediated injury in vivo progresses in the absence of effector T cells
BA Small et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Regulation of MAP kinase activity by peptide receptor signalling pathway: Paradigms of multiplicity
C Liebmann
CELLULAR SIGNALLING (2001)
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity
HR Tsou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
The 4-anilinoquinazoline class of inhibitors of the erb B family of receptor tyrosine kinases
WA Denny
FARMACO (2001)
The protein tyrosine kinase family of the human genome
DR Robinson et al.
ONCOGENE (2000)
Cell signaling by receptor tyrosine kinases
J Schlessinger
CELL (2000)
Tyrosine kinase inhibitors.: 17.: Irreversible inhibitors of the epidermal growth factor receptor:: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
JB Smaill et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Virus clearance through apoptosis-dependent phagocytosis of influenza a virus-infected cells by macrophages
I Fujimoto et al.
JOURNAL OF VIROLOGY (2000)
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts
PW Vincent et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Share Paper
